in10018
Small moleculeexperimental
Clinical trial activity
14 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04109456)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174908 | Phase 3 | Sep 30, 2025 | Chinese Academy of Medical Sciences, InxMed (Shanghai) Co., Ltd., Jiao Tong University |
| NCT06946927 | Phase 1 | Jun 6, 2025 | Jemincare, Shantou University |
| NCT06708663 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Government of China |
| NCT06654011 | Phase 2 | Nov 1, 2024 | Huazhong University of Science and Technology |
| NCT06030258 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2023 | InxMed (Shanghai) Co., Ltd., Peking University |
| NCT05982522 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2023 | InxMed (Shanghai) Co., Ltd. |
| NCT05994131 | Phase 1/Phase 2 (Phase 2) | Jul 13, 2023 | Huazhong University of Science and Technology, InxMed (Shanghai) Co., Ltd. |
| NCT05827796 | Phase 1/Phase 2 (Phase 2) | Dec 8, 2022 | InxMed (Shanghai) Co., Ltd. |
| NCT05379946 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2022 | Chinese Academy of Medical Sciences, InventisBio Inc., InxMed (Shanghai) Co., Ltd. |
| NCT06014528 | Phase 2 | Sep 6, 2022 | InxMed (Shanghai) Co., Ltd. |
| NCT05830539 | Phase 1/Phase 2 (Phase 2) | Mar 10, 2022 | Chinese Academy of Medical Sciences, Fudan University, InxMed (Shanghai) Co., Ltd. |
| NCT05551507 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2020 | InxMed (Shanghai) Co., Ltd., Peking University |
| NCT05327231 | Phase 1 | Jul 9, 2020 | Huazhong University of Science and Technology, InxMed (Shanghai) Co., Ltd. |
| NCT04109456 | Phase 1 | Nov 30, 2019 | InxMed (Shanghai) Co., Ltd. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| InxMed (Shanghai) Co., Ltd. | For profit | 11 | 10 | 3 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 2 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 3 | 1 | 2 | 2020 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| InventisBio Inc. | For profit | 1 | 1 | 1 | 2022 |
| Jemincare | For profit | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2025 |
10 organizations
Page 1 / 1